Kenneth Wu, Benjamin D Hopkins, Roberto Sanchez, Robert J DeVita, Zhen-Qiang Pan
{"title":"小分子调节剂靶向Cullin-RING E3泛素连接酶4","authors":"Kenneth Wu, Benjamin D Hopkins, Roberto Sanchez, Robert J DeVita, Zhen-Qiang Pan","doi":"10.33696/Signaling.2.051","DOIUrl":null,"url":null,"abstract":"<p><p>Cullin-RING E3 ubiquitin ligase 4 (CRL4) plays an essential role in cell cycle progression. Recent efforts using high throughput screening and follow up hit-to-lead studies have led to identification of small molecules <b>33-11</b> and <b>KH-4-43</b> that inhibit E3 CRL4's core ligase complex and exhibit anticancer potential. This review provides: 1) an updated perspective of E3 CRL4, including structural organization, major substrate targets and role in cancer; 2) a discussion of the challenges and strategies for finding the CRL inhibitor; and 3) a summary of the properties of the identified CRL4 inhibitors as well as a perspective on their potential utility to probe CRL4 biology and act as therapeutic agents.</p>","PeriodicalId":73645,"journal":{"name":"Journal of cellular signaling","volume":"2 3","pages":"195-205"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486283/pdf/","citationCount":"0","resultStr":"{\"title\":\"Targeting Cullin-RING E3 Ubiquitin Ligase 4 by Small Molecule Modulators.\",\"authors\":\"Kenneth Wu, Benjamin D Hopkins, Roberto Sanchez, Robert J DeVita, Zhen-Qiang Pan\",\"doi\":\"10.33696/Signaling.2.051\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Cullin-RING E3 ubiquitin ligase 4 (CRL4) plays an essential role in cell cycle progression. Recent efforts using high throughput screening and follow up hit-to-lead studies have led to identification of small molecules <b>33-11</b> and <b>KH-4-43</b> that inhibit E3 CRL4's core ligase complex and exhibit anticancer potential. This review provides: 1) an updated perspective of E3 CRL4, including structural organization, major substrate targets and role in cancer; 2) a discussion of the challenges and strategies for finding the CRL inhibitor; and 3) a summary of the properties of the identified CRL4 inhibitors as well as a perspective on their potential utility to probe CRL4 biology and act as therapeutic agents.</p>\",\"PeriodicalId\":73645,\"journal\":{\"name\":\"Journal of cellular signaling\",\"volume\":\"2 3\",\"pages\":\"195-205\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486283/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of cellular signaling\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33696/Signaling.2.051\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cellular signaling","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33696/Signaling.2.051","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Targeting Cullin-RING E3 Ubiquitin Ligase 4 by Small Molecule Modulators.
Cullin-RING E3 ubiquitin ligase 4 (CRL4) plays an essential role in cell cycle progression. Recent efforts using high throughput screening and follow up hit-to-lead studies have led to identification of small molecules 33-11 and KH-4-43 that inhibit E3 CRL4's core ligase complex and exhibit anticancer potential. This review provides: 1) an updated perspective of E3 CRL4, including structural organization, major substrate targets and role in cancer; 2) a discussion of the challenges and strategies for finding the CRL inhibitor; and 3) a summary of the properties of the identified CRL4 inhibitors as well as a perspective on their potential utility to probe CRL4 biology and act as therapeutic agents.